PATENT CLAIM ANALYSIS

Application Number: 15903503
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "006400"]

Abstract:
What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.

Claim (Index 41):
The method of  claim 39 , wherein the antibody binds to a ligand selected from CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT\u03b2R, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin \u03b1/TNF\u03b2, TNFR2, TNF\u03b1, LT\u03b2R, lymphotoxin \u03b11\u03b22, FAS, FASL, RELT, DR6, TROY, and NGFR.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 88.0
- Lexical Diversity: 1.34043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15354936', '15627766', '13957665', '15279361', '14610960']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.791666551958826
- 35 USC 102 Novelty (BERT): 0.5701290675655205
- Combined Prediction Score: 0.7695128035194954
- Mean Citation Score: 342.598746
- Max Citation Score: 541.30383
- Similarity Product: 329.4215189309084

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test